Neuroprotective effects of rotigotine in the acute MPTP-lesioned mouse model of Parkinson's disease

Neuroscience Letters

Volumn 432, Issue 1, 2008, Pages 30-34

  Scheller, Dieter ^a   Stichel Gunkel, Christine ^b   Lübbert, Hermann ^b   Porras, Gregory ^c   Ravenscroft, Paula ^d   Hill, Michael ^d   Bezard, Erwan ^c,d  

^a Schwarz Pharma AG   (Germany)

^b Biofrontera Pharmaceuticals GmbH   (Germany)

^c UMR 5287   (France)

^d Williams House   (United Kingdom)

Author keywords

Continuous administration; Dopamine agonist; Dopamine transporter; Rotigotine; Striatum; Substantia nigra pars compacta; Transdermal patch

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ROTIGOTINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DOSE RESPONSE; DRUG EFFECT; MALE; MOUSE; NERVE CELL DEGENERATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL;

ACUTE DISEASE; ADMINISTRATION, CUTANEOUS; ANIMALS; CORPUS STRIATUM; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; IODINE RADIOISOTOPES; MALE; MICE; MICE, INBRED C57BL; NERVE DEGENERATION; NEUROPROTECTIVE AGENTS; PARKINSONIAN DISORDERS; RADIOLIGAND ASSAY; RECEPTORS, DOPAMINE; SUBSTANTIA NIGRA; TETRAHYDRONAPHTHALENES; THIOPHENES;

EID: 38749085263     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2007.12.001     Document Type: Article

References (30)

1. Benner E.J., Mosley R.L., Destache C.J., Lewis T.B., Jackson-Lewis V., Gorantla S., Nemachek C., Green S.R., Przedborski S., and Gendelman H.E. Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 9435-9440
2. Bezard E., Dovero S., Belin D., Duconger S., Jackson-Lewis V., Przedborski S., Piazza P.V., Gross C.E., and Jaber M. Enriched environment confers resistance to MPTP and cocaine: involvement of dopamine transporter and neurotrophic factors. J. Neurosci. 23 (2003) 10999-11007
3. Bezard E., Dovero S., Prunier C., Ravenscroft P., Chalon S., Guilloteau D., Bioulac B., Brotchie J.M., and Gross C.E. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive MPTP-lesioned macaque model of Parkinson's disease. J. Neurosci. 21 (2001) 6853-6861
4. Bezard E., Gross C.E., Fournier M.C., Dovero S., Bloch B., and Jaber M. Absence of MPTP-induced neuronal death in mice lacking the dopamine transporter. Exp. Neurol. 155 (1999) 268-273
5. Brooks D.J., Ibanez V., Sawle G.V., Quinn N., Lees A.J., Mathias C.J., Bannister R., Marsden C.D., and Frackowiak R.S. Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann. Neurol. 28 (1990) 547-555
6. Dawson T.M., and Dawson V.L. Neuroprotective and neurorestorative strategies for Parkinson's disease. Nat. Neurosci. Suppl. 5 (2002) 1058-1061
7. Fahn S., and Sulzer D. Neurodegeneration and neuroprotection in Parkinson's disease. NeuroRx 1 (2004) 139-154
8. Franklin K.B., and Paxinos G. The Mouse Brain in Stereotaxic Coordinates (1997), Academic Press
9. Gross C.E., Ravenscroft P., Dovero S., Jaber M., Bioulac B., and Bezard E. Pattern of levodopa-induced striatal changes is different in normal and MPTP-lesioned mice. J. Neurochem. 84 (2003) 1246-1255
10. Ho A., and Blum M. Induction of interleukin-1 associated with compensatory dopaminergic sprouting in the denervated striatum of young mice: model of aging and neurodegenerative disease. J. Neurosci. 18 (1998) 5614-5629
11. Jaber M., Jones S., Giros B., and Caron M.G. The dopamine transporter: a crucial component regulating dopamine transmission. Mov. Disord. 12 (1997) 629-633
12. Jackson-Lewis V., Jakowec M., Burke R.E., and Przedborski S. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration 4 (1995) 257-269
13. Javitch J.A., D'Amato R.J., Strittmatter S.M., and Snyder S.H. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc. Natl. Acad. Sci. U.S.A. 82 (1985) 2173-2177
14. Joyce J.N. Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs. Pharmacol. Ther. 90 (2001) 231-259
15. Joyce J.N., Smutzer G., Whitty C.J., Myers A., and Bannon M.J. Differential modification of dopamine transporter and tyrosine hydroxylase mRNAs in midbrain of subjects with Parkinson's, Alzheimer's with parkinsonism, and Alzheimer's disease. Mov. Disord. 12 (1997) 885-897
16. Joyce J.N., Woolsey C., Ryoo H., Borwege S., and Hagner D. Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson's disease, and downregulates the dopamine transporter via the D3 receptor. BMC Biol. 2 (2004) 22
17. Kish S.J., Shannak K., and Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N. Engl. J. Med. 318 (1988) 876-880
18. Kuhn K., Wellen J., Link N., Maskri L., Lubbert H., and Stichel C.C. The mouse MPTP model: gene expression changes in dopaminergic neurons. Eur. J. Neurosci. 17 (2003) 1-12
19. Le W.D., and Jankovic J. Are dopamine receptor agonists neuroprotective in Parkinson's disease?. Drugs Aging 18 (2001) 389-396
20. Meissner W., Dovero S., Bioulac B., Gross C.E., and Bezard E. Compensatory regulation of striatal neuropeptide gene expression occurs before changes in metabolic activity of basal ganglia nuclei. Neurobiol. Dis. 13 (2003) 46-54
21. Meissner W., Hill M.P., Tison F., Gross C.E., and Bezard E. Neuroprotective strategies for Parkinson's disease: conceptual limits of clinical trials and animal models. Trends Pharmacol. Sci. 25 (2004) 249-253
22. Nair V.D., Olanow C.W., and Sealfon S.C. Activation of phosphoinositide 3-kinase by D2 receptor prevents apoptosis in dopaminergic cell lines. Biochem. J. 373 (2003) 25-32
23. Olanow C.W. The scientific basis for the current treatment of Parkinson's disease. Annu. Rev. Med. 55 (2004) 41-60
24. Schapira A.H. Neuroprotection and dopamine agonists. Neurology 58 (2002) S9-S18
25. Scheller D., Chan P., Li Q., Wu T., Zhang R., Guan L., Ravenscroft P., Guigoni C., Crossman A.R., Hill M., and Bezard E. Rotigotine treatment partially protects from MPTP toxicity in a progressive macaque model of Parkinson's disease. Exp. Neurol. 203 (2007) 415-422
26. Scheller D.K.A. Extended receptor profile of rotigotine, a non-ergolinic dopamine agonist being investigated in Parkinson's disease. Mov. Disord. 21 (2006) S75
27. Schmued L.C., and Hopkins K.J. Fluoro-Jade B: a high affinity fluorescent marker for the localization of neuronal degeneration. Brain Res. 874 (2000) 123-130
28. Snow B.J., Vingerhoets F.J.G., Langston J.W., Tetrud J.W., Sossi V., and Calne D.B. Pattern of dopaminergic loss in the striatum of humans with MPTP-induced parkinsonism. J. Neurol. Neurosurg. Psychiatry 68 (2000) 313-316
29. Vila M., Jackson-Lewis V., Vukosavic S., Djaldetti R., Liberatore G., Offen D., Korsmeyer S.J., and Przedborski S. Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 2837-2842
30. Wu D.C., Jackson-Lewis V., Vila M., Tieu K., Teismann P., Vadseth C., Choi D.K., Ischiropoulos H., and Przedborski S. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. J. Neurosci. 22 (2002) 1763-1771